Contraindicated (1)bortezomib will boost the stage or outcome of mavacamten by influencing hepatic enzyme CYP2C19 metabolism. Contraindicated. Powerful or moderate CYP2C19 inhibitors may possibly increase mavacamten systemic publicity, causing coronary heart failure due to systolic dysfunction. Monitor for hepatitis B virus in all cancer clients commencing systemic treatment. Determin... https://tienoxololfa35665.blogdomago.com/26349051/not-known-factual-statements-about-lenvatinib